Category

Daily Briefs

Daily Brief India: Indusind Bank and more

By | Daily Briefs, India

In today’s briefing:

  • Need to Reactivate the Stakeholders’ Relationship Committee in the Wake of the IndusInd Bank Fiasco


Need to Reactivate the Stakeholders’ Relationship Committee in the Wake of the IndusInd Bank Fiasco

By Hemindra Hazari

  • The rejection by shareholders of an independent director’s re-appointment reveals the growing influence of proxy advisory firms on institutional investors
  • Indian corporate boards appear ill-prepared to engage with stakeholders to provide valuable feedback 
  • Stakeholders Relationship Committee of the Board needs to reactivated and re-oriented to engage with stakeholders to improve governance

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief United States: Elastic NV and more

By | Daily Briefs, United States

In today’s briefing:

  • Elastic: 2Q’FY24 Earnings Review – Elastic Cloud Is a Bright Spot, PT Raised To $121


Elastic: 2Q’FY24 Earnings Review – Elastic Cloud Is a Bright Spot, PT Raised To $121

By Andrei Zakharov

  • Elastic NV (ESTC US) reported a solid quarter, reflecting strong cloud revenue growth, ~13% non-GAAP operating margin and rapid adoption of ESRE.
  • Elastic NV (ESTC US) shares rallied 35%+ during regular trading session and closed up ~37% on Friday at $110.20. I raised PT to $121 from $112.
  • However, I downgrade Elastic NV (ESTC US) to Equal-weight from Overweight on valuation and expect the stock to trade in-line with peers.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief Japan: Fast Retailing, Taisho Pharmaceutical Holdin, TSE Tokyo Price Index TOPIX and more

By | Daily Briefs, Japan

In today’s briefing:

  • March 2024 Nikkei 225 Rebal – Socionext, Disco, and a Consumer Goods Stock to ADD and ¥1trn To Trade
  • Taisho Pharmaceutical (4581 JP): Japan Catalyst Pushes for a Bump
  • MBOs Would Open the Door to Investment for Companies that Weren’t Invested for Fear Of “Value Trap”


March 2024 Nikkei 225 Rebal – Socionext, Disco, and a Consumer Goods Stock to ADD and ¥1trn To Trade

By Travis Lundy

  • Minimal changes in the rankings since last time. Socionext (6526), Disco (6146), and a Consumer Goods stock (Zozo (3092) top-ranked, Ryohin Keikaku (7453) a better choice) are ADDs.
  • The DELETEs are still Takara Holdings (2531), Pacific Metals (5541), Sumitomo Osaka Cement (5232) with a dark horse candidate in Hitachi Zosen (7004) to replace Takara.
  • There is the upweight to Nitori (9843) AND funkiness with Fast Retailing (9983) to consider. We are right on the threshold. The question is whether it gets “help” in January.

Taisho Pharmaceutical (4581 JP): Japan Catalyst Pushes for a Bump

By Arun George

  • Japan Catalyst’s press release supports the idea of a Taisho Pharmaceutical Holdin (4581 JP) MBO but not the proposed offer price as it implies a P/B less than 1.0x.
  • The press release is a discovery exercise encouraging other like-minded shareholders to show their hand. The shares are trading marginally above the JPY8,620 offer.
  • While justifiable, a bump is unlikely due to the lack of a substantial activist shareholder, irrevocables, no competing bid and the offer’s 55.5% premium to the undisturbed price.

MBOs Would Open the Door to Investment for Companies that Weren’t Invested for Fear Of “Value Trap”

By Aki Matsumoto

  • The fact that many IPO companies either don’t need to raise capital or don’t share the same goal of going public is the crux of the problem.
  • It would be conducive to improving quality of TSE as a whole if companies that cannot share the objectives of a listed company with shareholders are delisted through an MBO.
  • An MBO by the founding family would open the door to investment for companies that have been unable to invest for fear of falling into the “value trap.”

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief China: Want Want, Fu Shou Yuan, H World Group , Seazen (Formerly Future Land) and more

By | China, Daily Briefs

In today’s briefing:

  • Pair Trade:  Want Want (151 HK) And Mengniu (2319 HK)
  • Fu Shou Yuan (1448.HK) – Magic Is About to Disappear, but Is Still Undervalued
  • H World Group (1179 HK): Uniquely Well-Placed for Lower-Tier Markets
  • Morning Views Asia:


Pair Trade:  Want Want (151 HK) And Mengniu (2319 HK)

By Steve Zhou, CFA

  • Want Want (151 HK) and China Mengniu Dairy Co (2319 HK) are both fairly liquid names in the China consumer staples sector. 
  • Both companies trade at virtually the same forward PE of 14x.  However, I expect Want Want’s near term sales growth to be lower than market expectations.  
  • The upside risk for Want Want could be its overseas expansion efforts, as overseas sales now account for mid to high-single-digit of sales and grew high-teens yoy in FY1H24. 

Fu Shou Yuan (1448.HK) – Magic Is About to Disappear, but Is Still Undervalued

By Xinyao (Criss) Wang

  • The high growth in 23H1 is unsustainable. 23H2 YoY revenue growth would be single-digit. Due to 23H1’s high base, we cannot rule out the possibility of negative growth in 24H1.
  • In the case of lower-than-expected external M&A activities, Fu Shou Yuan has accumulated a large amount of cash, which would drag down ROE. So, current dividend policy still needs improvement. 
  • Fu Shou Yuan’s expansion would be relatively moderate. Double-digit revenue growth can still be expected in the long term. The market value of above RMB15 billion is more reasonable. 

H World Group (1179 HK): Uniquely Well-Placed for Lower-Tier Markets

By Osbert Tang, CFA

  • H World Group (1179 HK) has been over-penalised by market weakness as its share price was off 16.8% YTD. It turned around in 3Q23 and guidance for 4Q23 is solid.
  • Surge in operating and adjusted EBITDA margins indicated high operating leverage. Occupancy has not returned to 2019 level, but there will be more margin expansion when this happens.
  • 55% of rooms in China are of economy type, and 82% are in tier-2 and below cities. Such characteristics allow it to benefit from the prevailing consumption downgrade. 

Morning Views Asia:

By Charles Macgregor

Lucror Analytics Morning Views comprise our fundamental credit analysis, opinions and trade recommendations on high yield issuers in the region, based on key company-specific developments in the past 24 hours. Our Morning Views include a section with a brief market commentary, key market indicators and a macroeconomic and corporate event calendar.


    💡 Before it’s here, it’s on Smartkarma

    Sign Up for Free

    The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

    • ✓ Unlimited Research Summaries
    • ✓ Personalised Alerts
    • ✓ Custom Watchlists
    • ✓ Company Data and News
    • ✓ Events & Webinars



    Most Read: Zhongjin Gold Corp A, Shanxi Meijin Energy Co, Ltd., Hygon Information Technology C, Eoptolink Technology , KCE Electronics PCL, Uber Technologies , Taisho Pharmaceutical Holdin, China Tourism Group Duty Free Corp Ltd, Cosmo Energy Holdings and more

    By | Daily Briefs, Most Read

    In today’s briefing:

    • CSI300 Index Rebalance: 14 Changes & A Few Surprises
    • CSI500 Index Rebalance: 50 Changes a Side; Adds Gaining Ground on Deletes
    • CNI Semiconductor Chips Index Rebalance: Yet Another Index Inclusion for Hygon
    • ChiNext/​​ChiNext 50 Index Rebalance: Adds Outperforming Deletes Now
    • SET50 Index Rebalance Preview: KCE Could Replace TIDLOR
    • S&P500 Index Rebalance: Calling an UBER
    • Japan Activism:  Japan Catalyst Fund Calls Out Taisho Pharma Committee on MBO Price
    • [Blue Lotus Daily]: XPEV/NIO/BYD/TSLA LI/Geely/ACMR/ MU/NVDA/981.HK/1810.HK/000660.KS
    • 2024 High Conviction: China Tourism Group (601888 CH, BUY, TP:CNY106): See the Forest for the Trees
    • Mischief Managed! Iwatani Corp (8088) Buys Out Murakami-San’s Cosmo Energy Stake


    CSI300 Index Rebalance: 14 Changes & A Few Surprises

    By Brian Freitas

    • There are 14 changes for the Shanghai Shenzhen CSI 300 Inde (SHSZ300 INDEX) at the upcoming rebalance that will be implemented at the close of trading on 8 December.
    • While most changes are in line with forecasts, there are some stocks that have not been added or deleted as the index committee has used their discretion.
    • The adds outperformed the deletes in the first half of the year with performance staying stable over the second half of the year. Position for outperformance ahead of implementation.

    CSI500 Index Rebalance: 50 Changes a Side; Adds Gaining Ground on Deletes

    By Brian Freitas

    • There are 50 changes a side for the CSI Smallcap 500 Index at the upcoming rebalance that will be implemented at the close of trading on 8 December.
    • There are 15 stocks that overlap between the CSI 300 Index and the CSI Smallcap 500 Index and there will be opposing flows from passive trackers.
    • One way turnover at the rebalance is estimated at 9.56% leading to a one-way trade of CNY 6.04bn. Industrials and Information Technology gain index spots while Materials and Financial lose.

    CNI Semiconductor Chips Index Rebalance: Yet Another Index Inclusion for Hygon

    By Brian Freitas

    • There are 3 changes for the CNI Semiconductor Chips Index that will be implemented at the close on 8 December.
    • This is yet another index inclusion for Hygon Information Technology C (688041 CH) – the stock continues to move higher on expected passive buying over the next two weeks.
    • Over the last 6 months, the adds have underperformed the deletes but there has been a significant improvement in performance over the last 2 months.

    ChiNext/​​ChiNext 50 Index Rebalance: Adds Outperforming Deletes Now

    By Brian Freitas

    • There will be 6 changes for the ChiNext Index (SZ399006 INDEX) and 5 changes for the ChiNext 50 Index. Implementation is at the close on 8 December.
    • There is a lot of overlap between the adds and deletes across both indices with the one-way trade across both indices estimated to be CNY 2.4bn.
    • The adds and deletes have drifted lower over the last few months. However, the adds have outperformed the deletes significantly in the last month.

    SET50 Index Rebalance Preview: KCE Could Replace TIDLOR

    By Brian Freitas


    S&P500 Index Rebalance: Calling an UBER

    By Brian Freitas


    Japan Activism:  Japan Catalyst Fund Calls Out Taisho Pharma Committee on MBO Price

    By Travis Lundy

    • Japan Catalyst Fund is a relatively young effort in the Japan “engagement activism” space, having been founded by Monex Group in September 2019. Total assets remain apparently small.
    • Championed by Monex Group founder Oki Matsumoto, despite small AUM, the fund has decent access. As of end-October, Taisho Pharmaceutical Holdings (4581 JP) was #5 and 5.26%. Now it’s #2.
    • Friday, they released a statement about the MBO. It isn’t a barn-burner, but the stock has traded through terms since announcement at a too-low price. And nobody else has commented.

    [Blue Lotus Daily]: XPEV/NIO/BYD/TSLA LI/Geely/ACMR/ MU/NVDA/981.HK/1810.HK/000660.KS

    By Eric Wen

    • XPEV/NIO/BYD/TSLA: Luxeed S7 officially launched, price lowered by RMB 8,200 (-)
    • NIO: Geely and NIO enter into strategic cooperation agreement for battery swapping (+)
    • ACMR/ MU/ NVDA/ 981.HK/ 1810.HK/ 000660.KS: CXMT launches first domestic LPDDR5 RAM (+/+/+/-/-/-)

    2024 High Conviction: China Tourism Group (601888 CH, BUY, TP:CNY106): See the Forest for the Trees

    By Mohshin Aziz

    • China stock market despair has brought down  China Tourism Group Duty Free Corp Ltd (601888 CH) to its lowest forward valuation in the past ten years   
    • Poised for long-term growth, Chinese are buying albeit more prudently, government supportive on promoting domestic consumption, efficiency enhancements will lower cost and boost margins 
    • Using the company’s lowest recorded PE ratio in the past 10 years of 23.2x into FY24, we derive a target price of CNY106 (+21% UPSIDE)  

    Mischief Managed! Iwatani Corp (8088) Buys Out Murakami-San’s Cosmo Energy Stake

    By Travis Lundy

    • The question of how Murakami-san would get out of his stake in Cosmo Energy Holdings (5021 JP) was always a biggie. He likes to sell stock in tender offer buybacks.
    • Cosmo wasn’t going to do that for him. They promised dividends and a high payout ratio, but that left the question was how he was going to get out. 
    • A semi-obvious solution was to find a corporate partner to buy his stake and today, Iwatani Corp (8088 JP) announced that it had bought 19.86% of Murakami-san’s 20.01% holding.

    💡 Before it’s here, it’s on Smartkarma

    Sign Up for Free

    The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

    • ✓ Unlimited Research Summaries
    • ✓ Personalised Alerts
    • ✓ Custom Watchlists
    • ✓ Company Analytics and News
    • ✓ Events & Webinars



    Daily Brief Industrials: Uber Technologies , Taiwan Secom and more

    By | Daily Briefs, Industrials

    In today’s briefing:

    • S&P500 Index Rebalance: Calling an UBER
    • Quiddity TDIV/​50/​100 Dec 23 Rebal: Inflow Names Could Outperform Outflow Names
    • Index Rebalance & ETF Flow Recap: KWEB, CSI300/500, STAR50, SSE50, ChiNext, SET50, Chips, Denso, SPX


    S&P500 Index Rebalance: Calling an UBER

    By Brian Freitas


    Quiddity TDIV/​50/​100 Dec 23 Rebal: Inflow Names Could Outperform Outflow Names

    By Janaghan Jeyakumar, CFA

    • The index changes for the T50/100 index family and the TDIV index were confirmed after market close on Friday 1st December 2023.
    • The index changes were mostly in line with our final expectations.
    • In this insight, we take a close look at the breakdown of our final flow expectations for the upcoming Inclusion/Exclusion and Capping events.

    Index Rebalance & ETF Flow Recap: KWEB, CSI300/500, STAR50, SSE50, ChiNext, SET50, Chips, Denso, SPX

    By Brian Freitas

    • The announcement of the inclusion of Uber Technologies (UBER US) in the S&P 500 INDEX was a big one last week. There were announcements for some other indices too.
    • There are many indices in China that will be rebalanced at the close on Friday, the biggest being the CSI 300, CSI 500, STAR50, SSE50 and KWEB US.
    • Relatively quiet in ETF world with net inflows to China focused ETFs and net outflows for Japan.

    💡 Before it’s here, it’s on Smartkarma

    Sign Up for Free

    The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

    • ✓ Unlimited Research Summaries
    • ✓ Personalised Alerts
    • ✓ Custom Watchlists
    • ✓ Company Data and News
    • ✓ Events & Webinars



    Daily Brief Energy/Materials: Cosmo Energy Holdings , Fufeng, Boss Resources and more

    By | Daily Briefs, Energy & Materials Sector

    In today’s briefing:

    • Mischief Managed! Iwatani Corp (8088) Buys Out Murakami-San’s Cosmo Energy Stake
    • Asian Dividend Gems: Fufeng
    • Quiddity ASX Dec 23 Index Rebal: Beware of Pre-Positioning


    Mischief Managed! Iwatani Corp (8088) Buys Out Murakami-San’s Cosmo Energy Stake

    By Travis Lundy

    • The question of how Murakami-san would get out of his stake in Cosmo Energy Holdings (5021 JP) was always a biggie. He likes to sell stock in tender offer buybacks.
    • Cosmo wasn’t going to do that for him. They promised dividends and a high payout ratio, but that left the question was how he was going to get out. 
    • A semi-obvious solution was to find a corporate partner to buy his stake and today, Iwatani Corp (8088 JP) announced that it had bought 19.86% of Murakami-san’s 20.01% holding.

    Asian Dividend Gems: Fufeng

    By Douglas Kim

    • Fufeng (546 HK)’s core businesses include food additives such as MSG, animal nutrition, high-end amino acids, and colloid such as xanthan gum. 
    • Xantham gum is increasingly becoming popular as millions of people around the world purchase gluten free foods.
    • Fufeng’s dividend yield averaged 7.5% annually from 2018 to 2022. Its current dividend yield is about 11-12%. Fufeng is trading at P/E of 2.9x and EV/EBITDA of 1.8x in 2024. 

    Quiddity ASX Dec 23 Index Rebal: Beware of Pre-Positioning

    By Janaghan Jeyakumar, CFA

    • The December 2023 review results for ASX indices were announced after the close on Friday 1st December 2023.
    • There will be three ADDs and thee DELs for the ASX 200 index. There are no changes for ASX 20, 50, and 100.
    • In this insight, we take a look at our index flow expectations, trends in short interest, and the recent trading performance of the names involved in the ASX 200 changes.

    💡 Before it’s here, it’s on Smartkarma

    Sign Up for Free

    The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

    • ✓ Unlimited Research Summaries
    • ✓ Personalised Alerts
    • ✓ Custom Watchlists
    • ✓ Company Data and News
    • ✓ Events & Webinars



    Daily Brief TMT/Internet: Hollysys Automation Technologies, Bilibili and more

    By | Daily Briefs, TMT/Internet

    In today’s briefing:

    • (Mostly) Asia-Pac Weekly Risk Arb Wrap: Glosel, CIMC, Orecorp, Tietto Mineral, Lansen Pharmaceutical
    • [Bilibili Inc. (BILI US, SELL, TP US$9) Target Price Change]: Niche Player Faces Market Saturation


    (Mostly) Asia-Pac Weekly Risk Arb Wrap: Glosel, CIMC, Orecorp, Tietto Mineral, Lansen Pharmaceutical

    By David Blennerhassett


    [Bilibili Inc. (BILI US, SELL, TP US$9) Target Price Change]: Niche Player Faces Market Saturation

    By Ying Pan

    • Bilibili reported  C3Q23 revenue, operating profit, and GAAP net income inline, 4.37%, (21.6%) vs. consensus. The miss was primarily due to ineffective investment in game studio and related costs.
    • We are bearish on BILI’s game pipeline as ACGN is already a crowded market with well-entrenched competitors
    • We maintain our SELL rating and cut the TP from US$ 12.3 to US$ 9.04, and consider that it is unlikely for them to breakeven in 2024

    💡 Before it’s here, it’s on Smartkarma

    Sign Up for Free

    The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

    • ✓ Unlimited Research Summaries
    • ✓ Personalised Alerts
    • ✓ Custom Watchlists
    • ✓ Company Data and News
    • ✓ Events & Webinars



    Daily Brief Health Care: Taisho Pharmaceutical Holdin, Zhejiang Orient Gene Biotech C, D.Western Therapeutics Institute Inc. and more

    By | Daily Briefs, Healthcare

    In today’s briefing:

    • Japan Activism:  Japan Catalyst Fund Calls Out Taisho Pharma Committee on MBO Price
    • China Healthcare Weekly (Dec.1) – Medical Device VBP, Biotech to Breakeven Soon, Orient Gene Biotech
    • 3Q Follow-Up – D. Western Therapeutics Institute (DWTI) (4576 JP)


    Japan Activism:  Japan Catalyst Fund Calls Out Taisho Pharma Committee on MBO Price

    By Travis Lundy

    • Japan Catalyst Fund is a relatively young effort in the Japan “engagement activism” space, having been founded by Monex Group in September 2019. Total assets remain apparently small.
    • Championed by Monex Group founder Oki Matsumoto, despite small AUM, the fund has decent access. As of end-October, Taisho Pharmaceutical Holdings (4581 JP) was #5 and 5.26%. Now it’s #2.
    • Friday, they released a statement about the MBO. It isn’t a barn-burner, but the stock has traded through terms since announcement at a too-low price. And nobody else has commented.

    China Healthcare Weekly (Dec.1) – Medical Device VBP, Biotech to Breakeven Soon, Orient Gene Biotech

    By Xinyao (Criss) Wang

    • The national centralized procurement of high-value medical consumables for intraocular lens (IOL) and medical consumables related to sports medicine released results, with lower than expected price reductions. 
    • Despite anti-corruption campaign, the business/profit model validation process of Chinese Biotech has not slowed down. There’s a chance to see Chinese Biotech turn losses into profits in 2024-2025.
    • Zhejiang Orient Gene Biotech (688298 CH) once brought considerable returns to investors, but now the beautiful story is over.After deletion from CSI Medical Service Index, share price could remain weak.

    3Q Follow-Up – D. Western Therapeutics Institute (DWTI) (4576 JP)

    By Sessa Investment Research

    • Major milestones with high expectations coming in the next 2-3 years: 1) Phase IIb US trials for H-1337 as “first choice as a second-line Glaucoma drug” for patients who do not respond to PGs
    • 2) 2023 application, 2024 approval and 2025 launch of DW-1002 in Japan, 2023 application/approval/launch in China, as well as expedited development of combination formula MembraneBlue-DualR (DW-1002 + trypan blue) in the US [NEW]
    • 3) clinical trials in 2024 in Japan and application for approval in 2025 of regenerative cell medicine DWR-2206 

    💡 Before it’s here, it’s on Smartkarma

    Sign Up for Free

    The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

    • ✓ Unlimited Research Summaries
    • ✓ Personalised Alerts
    • ✓ Custom Watchlists
    • ✓ Company Data and News
    • ✓ Events & Webinars



    Daily Brief Industrials: Uber Technologies , Taiwan Secom and more

    By | Daily Briefs, Industrials

    In today’s briefing:

    • S&P500 Index Rebalance: Calling an UBER
    • Quiddity TDIV/​50/​100 Dec 23 Rebal: Inflow Names Could Outperform Outflow Names
    • Index Rebalance & ETF Flow Recap: KWEB, CSI300/500, STAR50, SSE50, ChiNext, SET50, Chips, Denso, SPX


    S&P500 Index Rebalance: Calling an UBER

    By Brian Freitas


    Quiddity TDIV/​50/​100 Dec 23 Rebal: Inflow Names Could Outperform Outflow Names

    By Janaghan Jeyakumar, CFA

    • The index changes for the T50/100 index family and the TDIV index were confirmed after market close on Friday 1st December 2023.
    • The index changes were mostly in line with our final expectations.
    • In this insight, we take a close look at the breakdown of our final flow expectations for the upcoming Inclusion/Exclusion and Capping events.

    Index Rebalance & ETF Flow Recap: KWEB, CSI300/500, STAR50, SSE50, ChiNext, SET50, Chips, Denso, SPX

    By Brian Freitas

    • The announcement of the inclusion of Uber Technologies (UBER US) in the S&P 500 INDEX was a big one last week. There were announcements for some other indices too.
    • There are many indices in China that will be rebalanced at the close on Friday, the biggest being the CSI 300, CSI 500, STAR50, SSE50 and KWEB US.
    • Relatively quiet in ETF world with net inflows to China focused ETFs and net outflows for Japan.

    💡 Before it’s here, it’s on Smartkarma

    Sign Up for Free

    The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

    • ✓ Unlimited Research Summaries
    • ✓ Personalised Alerts
    • ✓ Custom Watchlists
    • ✓ Company Data and News
    • ✓ Events & Webinars